MapLight Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
MapLight Therapeutics, Inc. Common Stock cash flow-to-debt ratio. MapLight Therapeutics, Inc. Common Stock (MPLT) has a Cash Flow-to-Debt Ratio of -2.24x as of June 2026, meaning its operating cash flow of $-44.87 Million could theoretically repay -2% of its total liabilities ($20.05 Million) in one year. See how financially flexible is MapLight Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of MapLight Therapeutics, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for MapLight Therapeutics, Inc. Common Stock across 4 annual periods. Also explore MapLight Therapeutics, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
MapLight Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
MapLight Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for MapLight Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see MapLight Therapeutics, Inc. Common Stock cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.53x | $-138.14 Million | $21.14 Million | ▼ -80.1% |
| 2024 | -3.63x | $-78.81 Million | $21.72 Million | ▼ -40.4% |
| 2023 | -2.58x | $-52.01 Million | $20.13 Million | ▼ -80.0% |
| 2022 | -1.44x | $-26.58 Million | $18.52 Million | — |